Receipt date 2,04/28/2008

ARE TRADE

10589726 - GAU: 1647

## ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 1 OF 6

INFORMATION DISCLOSURE

(Use as many sheets as necessary)

STATEMENT LIST

Complete if Known
Application Number 10/589,726
Filing Date August 17, 2006
First Named Inventor Hawiger et al.
Group Art Unit 1647
Examiner Name Unassigned

			.U.S. P	ATTENT	DOGU	VIENTIS :		AND THE PERSON NAMED IN	
Examiner's	Cite	Document No.		Date		Name	Class	Subclass	Filing Date
Initials	No.	6,323,317	11/2	7/2001	Hilton	ot al			(ii appropriate
	A2	7,049,418		/2006	Hilton			<del>                                     </del>	
_	A3	6,905,842		/2005	+	et al.		-	
	A4	3,610,795	_	/1971	Antoi			1	
	A4					UMENITS		1	send-
Examiner's Initials	Cite No.	Foreign Patent Docu	ment		ate	SOME MISS.	Name		Translation Yes/No
*******	A5	WO 99/03993		1/28/19	8/1999 Schering Corporation				
	A6	EP0045665				Szelke et al			
			NON P	ATENT	DOCU	MENTS	ar light		200
Examiner's Initials	Cite No.		-11 -11		,	, Publisher, Relevant Pa		ce of Publication)	
	A7	Abrahmsen L et al., "Engineering subtilisin and its subtrates for efficient ligation of peptide bonds in aqueous solutions," Biochemistry, 30:4151-4159 1991							
	A8	Alexander and Douglas J. Hilton. "The role of suppressors cytokine signaling (SOCS)" 22:503–29, 2004							
	A9	Alexander et al. "Suppressors of Cytokine signaling Immune system," Nat Rev (SOCS) 2:1-7, 2002							
	A10	Alexander, W.S., "Suppressors of cytokine signalling (SOCS) in the immune system" Nat Rev Immunol 2, 410-6, 2002							
	A11	Almquist et al., "Synthesis and biological activity of a ketomethylene," J. Med. Chem 23:1392-1398 (1980)							
	A12	Arad, G., Levy, R., Hillman, D. & Kaempfer, R. "Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation." Nat Med 6, 414-21 (2000).							
	A13	Baggiolini M et al. "Interleukin-8, a chemotactic and inflammatory cytokine," FEBS Lett. 307:97-101, 1992							
	A14	Bagshawe, et al., "A cytotoxic agent can be generated selectively at cancer sites." Br. J. Cancer, 58:700-703, (1988)							
	A15	Bagshawe, K.D., "The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites." Br. J. Cancer, 60:275-281, (1989)							
	A16	Balaban, N. & Rasooly, A. "Analytical chromatography for recovery of small amounts of staphylococcal enterotoxins from food." Int J Food Microbiol 64, 33-40 (2001).					f		
	A17	Battelli, et al., "T lymphocyte killing by a xanthine-oxidase-containing immunotoxin." Cancillimmunol. Immunother., 35:421-425, (1992)					ancer		
	A18	Benner, "Expanding the genetic lexicon: incorporating non-standard amino acids into ribosome-based synthesis." TIB Tech, 12:158-163 (1994)					acids into	proteins by	
	A19	Bjorbaek, C.et al. "Th 30059-30065, 1999					eptin resista	nce." J. Biol	. Chem.274

Examiner Signature: Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 2 OF 6

INITAD	MATION DISCLOSURE	Com Application Number	plete if Known 10/589,726	
	MATION DISCLOSURE	Filing Date	August 17, 2006	
3	STATEMENT LIST	First Named Inventor	Hawiger et al.	
(Hsa	as many sheets as necessary)	Group Art Unit	1647	
(030	as many sheets as necessary,	Examiner Name		
			Unassigned	
A20	Brown and Greene, "Molecular and cell and Cell Biology 10:6, 399-409 (1991)			
A21	Cahill et al., "Site-specific mutagenesis	s with unnatural amino acids." TIBS, 14(10):400-403 (1989)		
A22	Car, B.D. et al. "Interferon gamma rece Med 179, 1437-44 (1994).	ptor deficient mice are resi	stant to endotoxic shock." J Exp	
A23	Cavaillon, J.M., Adib-Conquy, M., Fittin Scand J Infect Dis 35, 535-44 (2003).	g, C., Adrie, C. & Payen, D	. "Cytokine cascade in sepsis."	
A24	Clark Lewis I et al., "Chemical synthesis	s, purification, and characterization of two inflammatory (interleukin-8) and neutrophil activating peptid 2."		
A25	analogs and CXC chemokine hybrids."	ments for interleukin-8 function identified by design of J.Biol.Chem., 269:16075-16081 (1994)		
A26		M.J. & Lynch, J.P., 3rd. "Antimicrobial resistance among e care unit." Curr Opin Crit Care 9, 403-12 (2003).		
A27	Croker, B.A. et al. "SOCS3 negatively r (2003).	egulates IL-6 signaling in v	ivo." Nat Immunol 4, 540-5	
A28	Dawson et al. Synthesis of Proteins by	Dawson et al. Synthesis of Proteins by Native Chemical Ligation. Science, 266:776 779, 1994		
A29	De Lisle Milton, R.C. et al., "Synthesis of Proteins by Chemical Ligation of Unprotected Peptide Segments: Mirror-Image Enxyme Molecules, D- & L-HIV Protease Analogs" Techniques in Protein Chemistry IV. Academic Press, New York, pp. 257 267 (1992)			
A30	Dinges, M.M., Orwin, P.M. & Schlievert Rev 13, 16-34, (2000).	, P.M. "Exotoxins of Staphy	vlococcus aureus." Clin Microbio	
A31	Drakas R et al. "A modified tandem affii complexes in mammalian cells." Protect		ue for the purification of protein	
A32	Emanuelli, B. et al, "SOCS-3 Is an insul Chem. 275, 15985-15991 (2000)		tor of insulin signaling." J.Biol.	
A33	Fey, P.D. et al. "Comparative molecular	Fey, P.D. et al. "Comparative molecular analysis of community- or hospital-acquired methicil resistant Staphylococcus aureus." Antimicrob Agents Chemother 47, 196-203 (2003).		
A34	Fitzgerald, K.A. et al. "LPS-TLR4 signal	Fitzgerald, K.A. et al. "LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapter TRAM and TRIF." J Exp Med 198, 1043-55 (2003).		
A35		Hann M. et al. "On the double bond isostere of the peptide bond: preparation of an enkephalin analogue." Chem. Soc Perkin, 307-314 (1982)		
A36	Hawiger, J. "Cellular import of functional Immunol 9, 189-94 (1997).			
A37	Hawiger, J. "Innate immunity and inflam 109 (2001).			
A38	Hawiger, J. "Noninvasive intracellular d Chem Biol 3, 89-94 (1999).			
A39	Hoebe, K. et al. "Identification of Lps2 a Nature 424, 743-8 (2003).	as a key transducer of MyD	88-independent TIR signaling."	

Examiner Signature:	Date Considered:					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if						
not in conformance and not considered. Include con	w of this form with next communication to applicant					

#### ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 3 OF 6

		Complete if Known		
INFORMATION DISCLOSURE STATEMENT LIST		Application Number	10/589,726	
		Filing Date	August 17, 2006	
		First Named Inventor	Hawiger et al.	
(Use a	s many sheets as necessary)	Group Art Unit	1647	
		Examiner Name	Unassigned	
A40	Holladay et al. "Synthesis of hydroxyeth	nlyene and ketomethylene	dipeptide isosteres,	
	Tetrahedron." Lett 24:4401-4404 (1983	3)		
A41	Hotamisligil, G. S., "Inflammatory pathw 55,(2003)	vays and insulin action.", G	.S. Int. J. Obes 27, S53-	
A42	Hruby, "Conformational restrictions of b Life Sci 31:189-199 (1982)	iologically active peptides	via amino acid chain groups."	
A43	Hudson, D. et al., "Methionine enkepha support." Int J Pept Prot Res 14:177-18		. I. Synthesis on a phenolic resi	
A44	Hughes et al.," Monoclonal antibody tar Research, 49:6214-6220, (1989)		se lung in vivo." Cancer	
A45	Ibba and Hennecke, "Towards engineer natural amino acids." Bio/technology, 1:		d incorporated in vivo of non-	
A46	Ibba,M., "Strategies for in vitro and in vi Biotechnology & Genetic Engineering F	ivo translation with non-nat		
A47		Inthetic oligonucleotides." Rev. Biochem. 53:323-356 (1984)		
A48	Inagaki-Ohara K, Hanada T, Yoshimura A., "Negative regulation of cytokine signaling and inflammatory diseases." Curr Opin Pharmacol. 3:435-42 2003.			
A49	Ivashkiv LB, Tassiulas I., "Can SOCS make arthritis better?" J Clin Invest.; 111, 795-7 2003			
A50	Jaeger et al., "Predicting optimal and suboptimal secondary structure for RNA." Methods Enzym 183:281-306, 1989			
A51	Jaeger et al., "Improved predictions of s 86:7706-7710, 1989	secondary structures for Rh	NA." Proc. Natl. Acad. Sci. USA	
A52	Jennings-White et al., "Synthesis of ke 23:2533-2534 (1982)	tomethylene analogs of dip	peptides." Tetrahedron Lett	
A53	Jo et al., "Intracellular Protein Therapy Med., 11, 892-898 2005	with SOCS3 Inhibits Inflam	mation and Apoptosis." Nature	
A54	Jo, D. et al., "Cell cycle-dependent tran Cell Biochem 89, 674-87 (2003).	sduction of cell-penetrating	Cre recombinase proteins." J	
A55			with a cell-permeable Cre	
A56	Krebs, D.L. & Hilton, D.J. "SOCS protei 19, 378-87 (2001).		cytokine signaling." Stem Cells	
A57	Krebs, D.L. & Hilton, D.J. "SOCS: physical 2813-9 (2000).			
A58	Kunkel et al. "Rapid and efficient site-sp Enzymol. 1987:154:367, 1987	pecific mutagenesis withou	t phenotypic selection." Method	
A59	Lang, R. et al., "SOCS3 regulates the p			
A60	Larsen et al., "Suppressors of Cytokine 12, pages 833-844	Signaling: SOCS." APMIS	December 2002, Vol 110. No.	
A61	Lee, J.Y. & Sullivan, K.E., "Gamma inte transcription to induce tumor necrosis fa	, , ,		
ner Signatu		Date Considered:		

not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if

# ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 4 OF 6

			plete if Known		
	MATION DISCLOSURE	Application Number	10/589,726		
S <sup>-</sup>	TATEMENT LIST	Filing Date	August 17, 2006		
		First Named Inventor	Hawiger et al.		
(Use a	s many sheets as necessary)	Group Art Unit	1647		
		Examiner Name	Unassigned		
A62	Letsinger et al., "Cholesteryl-conjugate	d oligonucleotides: Synthe	sis properties and activity as		
	inhibitors of replication of human immur 86, 6553 6556, 1989	nodeficiency virus cell cultu	re." Proc. Natl. Acad. Sci. USA,		
A63	Litzinger and Huang, Biochimica et Biop	ohysica Acta, 1104:179-18	7, (1992)		
A64	Liu, D. et al. "Suppression of Staphyloco Inhibitor." J Biol Chem 279, 19239-46 (2		d Toxicity by a Nuclear Import		
A65	Madsen, J.M. "Toxins as weapons of m		son and contrast with biological-		
	warfare and chemical-warfare agents."				
A66	Mattix, M.E., Hunt, R.E., Wilhelmsen, C				
	staphylococcal enterotoxin B-induced p	ulmonary lesions in rhesus	monkeys (Macaca mulatta)."		
	Toxicol Pathol 23, 262-8 (1995).				
A67	Miethke, T. et al. "T cell-mediated lethal				
		ole of tumor necrosis factor." J Exp Med 175, 91-98 (1992).			
A68	Morley, "Modulation of the Action of reg	ulatory peptides by structu	ral modification." Trends Pharm		
	Sci pp. 463-468,1980				
A69		exoxyoligonucleotides by t	exyoligonucleotides by the modified trimester method."		
A70	Methods Enzymol., 65:610-620 (1980)	athed applicable to the example for similarities in the amine			
A70	Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence of two proteins." J. MoL Biol. 48: 443-453 (1970)				
A71	Nielsen et al., "Petide nucleic acid (PNA	A). A DNA mimic with a per	otide backbone." Bioconjug.		
	Chem. 5:3-7 (1994)		100101		
A72	NIH Grant No. HL68744. "Functional G				
A73	NIH Grant No. HL69542. "Superantigen	n-Induced Vascular Injury a	nd DIC" 3/27/01		
A74	O'Keefe, G.M., Nguyen, V.T., Ping Tan				
	II transactivator promoter IV in macroph		ement of the suppressors of		
1.75	cytokine signaling-1 protein." J Immuno	166, 2260-9 (2001).			
A75	Oshiumi, H. et al. "TIR-containing adapt				
A76		nterferon-beta." J Biol Chem 278, 49751-62 (2003). for biological sequence comparison." Proc. Natl. Acad. Sci.			
A/6	U.S.A. 85: 2444 - 2448 (1988)	or biological sequence con	ipanson. Froc. Nati. Acad. Sci.		
A77		e 55 kd tumor necrosis factor receptor are resistant to onocytogenes infection." Cell 73, 457-67 (1993). ijugates for the treatment of cancer." Immunolog. Reviews,			
1 7"					
A78					
	129:57-80, (1992)	- <b>g</b>	<b>,</b>		
A79	Poltorak, A. et al. "Defective LPS signal gene." Science 282, 2085-8 (1998).	ling in C3H/HeJ and C57Bl	L/10ScCr mice: mutations in T/r4		
A80	Prescilla et al. http://www.emedicine.co	m, Immunology of Transpla	ant Rejection, updated June 20,		
A81	Rajagopalan, G., Smart, M.K., Krco, C., HLA-DQ molecules and lymphocyte de 1774-83 (2002).				

Examiner Signature:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 5 OF 6

			plete if Known	
INFORM	MATION DISCLOSURE	Application Number	10/589,726	
S	TATEMENT LIST	Filing Date	August 17, 2006	
		First Named Inventor	Hawiger et al.	
(Use a	s many sheets as necessary)	Group Art Unit	1647	
		Examiner Name	Unassigned	
A82	Rizo and Gierasch, "Constrained peption	des: models of bioactive pe	ptides and protein	
	substructures." Ann. Rev. Biochem. 61	·	F	
A83		nide prodrug treatment of human tumor cells targeted with a		
	monoclonal-enzyme conjugate." Bioche	em. Pharmacol. 42:2062-2065. (1991)		
A84		hritis: can suppressors of cytokine signaling (SOCS)		
	suppress rheumatoid arthritis?" J Clin II			
A85	Rui, L., Yuan, M., Frantz, D., Shoelson		and SOCS-3 block insulin	
	signaling by ubiquitin-mediated degrad	ation of IRS1 and IRS2." J	Biol Chem 277, 42394-8 (2002).	
A86	Sambrook et al., Molecular Cloning: A			
	Laboratory Press, Cold Spring Harbor,	N.Y., 1989) Chapter 5 "Enz	zymes Used in Molecular	
	Cloning"		•	
A87	Sambrook et al., Molecular Cloning: A			
	Laboratory Press, Cold Spring Harbor,	N.Y., 1989) Chapter 6 "Gel	Electrophoresis of DNA"	
A88	Schnolzer, M et al., "Constructing prote	eins by dovetailing unproted	ted synthetic peptides:	
	Backbone-engineered HIV protease."	Science, 256:221-5 (1992)		
A89	Senter, et al., "Generation of 5-flourour	acil from 5-fluorocytosine b	y monoclonal antibody-cytosine	
	deaminase conjugates." Bioconjugate			
A90	Senter, et al., "Generation of cytotoxic	agents by targeted enzyme	s." Bioconjugate Chem., 4:3-9,	
	(1993)			
A91	Shouda, T. et al., "Induction of the cyto			
	for treating inflammatory arthritis." J Cli			
A92	Smith and Waterman, Comparison of b			
A93	Spatola et al., "Structure-activity relatio	•	• •	
	thimethylene amide bond surrogates."			
A94		3), Vol. 1, Issue 3, Peptide Backbone Modifications: A		
	Structure-Activity Analysis of Peptides	Containing Amide Bond Su	rrogates. (general review), Chap	
	5., pages 267 - 357			
A95	Starr R, Hilton DJ SOCS: suppressors	of cytokine signaling. Int J	Biochem Cell Biol.30(10):1081-5	
	(1998 Oct).		7.11	
A96		ducible inhibitors of signaling." Nature 387, 917-21 (1997)		
A97	Stoiber, D. et al. "Lipopolysaccharide in			
	cytokine signaling 3 and suppresses signaling 3		se to the activating factor IFN-	
	gamma." J Immunol 163, 2640-7 (1999			
A98	Suzuki, A. et al. "CIS3/SOCS3/SSI3 pla		ole in STAT3 activation and	
	intestinal inflammation." J Exp Med 193			
A99	Thorson et al., "A Biosynthetic Approac		Innatural Amino Acids Into	
	Proteins" Methods in Molecular Biology			
A100	Uysal, K.T. et al, "Protection from obes	ity-induced insulin resistan	ce in mice lacking TNF function."	
100	Nature 389:610-614 1997		for the classification of	
A101	Veach, R.A. et al. "Receptor/transporte		tunctional peptides across the	
	plasma membrane." J Biol Chem 279,	11425-31 (2004).		

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Receipt date: 04/28/2008

10589726 - GAU: 1647

# ATTORNEY DOCKET NO. 22000.0129U2 APPLICATION NO. 10/589,726 SHEET 6 OF 6

				plete if Known	
	INFORM	IATION DISCLOSURE	Application Number	10/589,726	
	ST	ATEMENT LIST	Filing Date	August 17, 2006	
			First Named Inventor	Hawiger et al.	
	(Use as	s many sheets as necessary)	Group Art Unit	1647	
			Examiner Name	Unassigned	
	A102	Yasuda, S., Nagaki, M. & Moriwaki, H. lethal shock in endotoxin-resistant C3l Endotoxin Res 8, 253-61 (2002).			
	A103	Yasukawa, H. et al. "IL-6 induces an a macrophages." Nat Immunol 4, 551-6		n the absence of SOCS3 in	
_	A104	Yasukawa, H., Sasaki, A. & Yoshimura Annu Rev Immunol 18, 143-64 (2000)	a, A. "Negative regulation of	cytokine signaling pathways."	
	A105	Yeung, R.S. et al. "Human CD4 and hi	human major histocompatibility complex class II (DQ6) superantigen-induced septic shock." Eur J Immunol 26, 1074		
	A106	Zhang, J.G. et al. "The SOCS box of s of cytokine action in vivo." Proc Natl A			
	A107	Zoller, "New recombinant DNA method Biotechnology, 3:348-354 (1992)	dology for protein engineerin	ng." Current Opinion in	
	A108	Zuker, "On finding all suboptimal foldi	ngs of an RNA molecule." M	1. Science 244:48-52, 1989	

Examiner Signature:	/Bridget E. Bunner/	Date Considered:	12/23/2009				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if							
not in conformance and not considered. Include copy of this form with next communication to applicant.							